Danae Yiannakou

Mrs. Danae Yiannakou


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
KKKyriaki Katsaounou
Kyriaki Katsaounou
DYDanae Yiannakou
Danae Yiannakou
ENElpiniki Nikolaou
Elpiniki Nikolaou
CBCameron Brown
Cameron Brown
PVParis Vogazianos
Paris Vogazianos
Yiorgos ApidianakisYiorgos Apidianakis
Yiorgos Apidianakis
Microbiota and the metabolites they produce within the large intestine interact with the host epithelia under the influence of a range of host-derived metabolic, immune, and homeostatic factors. This complex host–microbe interaction affects intestinal tumorigenesis, but established microbial or metabolite profiles predicting colorectal cancer (CRC) risk are missing. Here, we aimed to identify fecal bacteria, volatile organic compounds (VOC), and their associations that distinguish healthy (non-adenoma, NA) from CRC prone (high-risk adenoma, HRA) individuals. Analyzing fecal samples obtained from 117 participants ≥15 days past routine colonoscopy, we highlight the higher abundance of Proteobacteria and Parabacteroides distasonis, and the lower abundance of Lachnospiraceae species, Roseburia faecis, Blautia luti, Fusicatenibacter saccharivorans, Eubacterium rectale, and Phascolarctobacterium faecium in the samples of HRA individuals. Volatolomic analysis of samples from 28 participants revealed a higher concentration of five compounds in the feces of HRA individuals, isobutyric acid, methyl butyrate, methyl propionate, 2-hexanone, and 2-pentanone. We used binomial logistic regression modeling, revealing 68 and 96 fecal bacteria-VOC associations at the family and genus level, respectively, that distinguish NA from HRA endpoints. For example, isobutyric acid associations with Lachnospiraceae incertae sedis and Bacteroides genera exhibit positive and negative regression lines for NA and HRA endpoints, respectively. However, the same chemical associates with Coprococcus and Colinsella genera exhibit the reverse regression line trends. Thus, fecal microbiota and VOC profiles and their associations in NA versus HRA individuals indicate the significance of multiple levels of analysis towards the identification of testable CRC risk biomarkers.

25 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
KKKyriaki Katsaounou
Kyriaki Katsaounou
DYDanae Yiannakou
Danae Yiannakou
ENElpiniki Nikolaou
Elpiniki Nikolaou
CBCameron Brown
Cameron Brown
PVParis Vogazianos
Paris Vogazianos
Yiorgos ApidianakisYiorgos Apidianakis
Yiorgos Apidianakis
Microbiota and the metabolites they produce within the large intestine interact with the host epithelia under the influence of a range of host-derived metabolic, immune, and homeostatic factors. This complex host-microbe interaction affects intestinal tumorigenesis but established microbial or metabolite profiles predicting colorectal cancer (CRC) risk are missing. Here we describe alterations in fecal bacteria and volatile organic compounds (VOC) in healthy (Non-Adenoma, NA) versus CRC prone (High-Risk Adenoma, HRA) individuals. Analyzing samples from 117 participants undergoing routine colonoscopy we highlight the higher abundance of Proteobacteria and Parabacteroides distasonis, and the lower abundance of Lachnospiraceae species, Roseburia faecis, Blautia luti, Fusicatenibacter saccharovorans, Eubacterium rectale and Phascolarctobacterium faecium, in the fecal samples of HRA individuals. Volatolomic analysis reveals higher concentration in the feces of HRA individuals of 5 compounds, isobutyric acid, methyl butyrate, methyl propionate, 2-hexanone and 2-pentanone. Interestingly, there is a level of complexity revealed by assessing fecal bacteria-VOC associations and another one by assessing differences in these associations between NA and HRA individuals. For example, isobutyric acid corelates positively with the Lachnospiraceae incertae sedis and Bacteroides genera in NA individuals, and negatively in HRA individuals. In contrast, Coprococcus and Colinsella genera correlate negatively with isobutyric acid in NA individuals, and positively in HRA individuals. The described differences in the fecal microbiota and VOC profiles and their associations in NA versus HRA individuals indicate the significance of multiple levels of combinatorial analysis towards the identification of testable CRC risk biomarkers.

Verified
Journal Article
Open access
PDF file
RSRosana Carvalho Silva
Rosana Carvalho Silva
DZDanae Stella Zareifi
Danae Stella Zareifi
DYDanae Yiannakou
Danae Yiannakou
Antreas AfantitisAntreas Afantitis
Antreas Afantitis
AMAlessandra Minelli
Alessandra Minelli
Major depressive disorder (MDD) is a prevalent psychiatric disorder in which epigenetic mechanisms, particularly DNA methylation (DNAm), may contribute to disease vulnerability and treatment response. Epigenome-wide association studies (EWAS) have increasingly investigated longitudinal methylomic changes associated with therapeutic interventions in depression; however, methodological heterogeneity limits comparability across studies. This critical review examined the methodologies and findings of longitudinal EWAS evaluating DNAm changes related to treatment response in MDD and treatment-resistant depression (TRD). A literature search identified seven studies published up to 20 June 2026. Six studies investigated non-pharmacological interventions, including electroconvulsive therapy, trauma-focused psychotherapy, and cognitive interventions, and one study explored pharmacotherapy. Considerable heterogeneity was observed regarding sample size, biospecimen type, methylation platforms, preprocessing pipelines, covariate adjustment, statistical modeling, and longitudinal sampling schedules. Most studies used Illumina EPIC array-based workflows and mixed-model analytical approaches, while one study employed sequencing-based methylation profiling. Overall, treatment-related methylation changes were modest and often limited to specific CpG sites or differentially methylated regions associated with immune, inflammatory, stress-related, and neurobiological pathways. Current evidence supports the feasibility of longitudinal EWAS approaches in depression research but highlights the need for larger cohorts, methodological standardization, and integration with multi-omics and clinical data to improve reproducibility and biomarker discovery.

24 December 2025 in Journal of Molecular Biology
Verified
Journal Article
Open access
DYDanae Yiannakou
Danae Yiannakou
CPConstantinos Papavasiliou
Constantinos Papavasiliou
DZDanae Zareifi
Danae Zareifi
Haralampos TzoupisHaralampos Tzoupis
Haralampos Tzoupis
KPKonstantinos D. Papavasileiou
Konstantinos D. Papavasileiou
Antreas AfantitisAntreas Afantitis
Antreas Afantitis
Drug repurposing is a widely adopted strategy aimed at identifying new therapeutic uses for drugs, offering a faster and more cost-effective alternative to traditional drug development. While the approach has gained significant traction, most existing computational tools are either focused on narrow analytical tasks, require extensive coding expertise or are disease-specific. To address these limitations, we present Repurposing Drug Explorer (ReDEx) - a user-friendly, zero-code platform that streamlines drug repurposing analysis through multiple interactive modules. ReDEx enables the exploration of drug-disease relationships using chemical structure-similarity-based, network-based, and functional methods within an integrated interface. Applied to Bipolar Disorder (BD), after excluding 3 of the 23 FDA approved/investigational drugs for BD, ReDEx successfully recovered all 3 in the top 15 out of 28,189 candidates. ReDEx is offered through a web interface on the Enalos Cloud Platform, enabling users to investigate individual drugs, diseases, or drug-disease pairs without programming skills.